Study of a new drug combined with irinotecan for small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug (cirtuvivint) combined with irinotecan, a common chemotherapy, for people whose small cell lung cancer has progressed after at least one prior treatment. The goal is to see if the combination helps control the cancer and whether it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have small cell lung cancer that has grown after at least one round of earlier chemotherapy.
- You are at least 18 years old.
- You are generally able to take care of yourself (ECOG performance status of 2 or less).
- Your blood counts and liver and kidney function are adequate (blood tests will be done to check).
- You have not had a bad reaction to irinotecan in the past and are not currently on other cancer treatments.
- You have no untreated brain metastases (or they have been treated and are stable; tiny, asymptomatic spots are allowed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new form of chemotherapy called irinotecan liposomes for people with advanced small cell lung cancer that has worsened after initial treatment. It aims to see if this drug can shrink tumors and improve survival.
This trial tests a new combination of drugs, including liposomal irinotecan, as the first treatment for extensive-stage small cell lung cancer. It aims to see if this combination can help control the cancer better than standard options.
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
This study tests a new combination of two drugs for small cell lung cancer that has grown after the first round of treatment. The goal is to see if the combination can slow or stop the cancer and to look for markers that predict who benefits.
This trial tests a new drug called IBI3009 for people with advanced small cell lung cancer that cannot be removed by surgery. It aims to see how safe the drug is and how well it works against the cancer.
This trial tests a combination of two medicines — a chemotherapy called irinotecan liposome and an immunotherapy called ivonescimab — for people whose small cell lung cancer has returned or progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.